跳至主要内容
临床试验/NCT06325826
NCT06325826进行中(未招募)不适用

The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs

Egyptian Liver Hospital1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2022年2月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
500
试验地点
1
主要终点
Hepatocellular Carcinoma

研究概览

简要总结

This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological response for hepatitis c virus after direct acting antiviral drugs and determine the group of these patients who require intensified surveillance.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients aged 18 years or older.
  • Patients with compensated advanced chronic liver disease (cACLD) according to Baveno VI consensus (F3-F4)
  • achieved SVR for HCV after DAAs.

排除标准

  • Previous interferon (IFN) treatment.
  • Hepatitis B virus (HBV) or human immune-deficiency virus (HIV) co-infection.
  • Current hepatocellular carcinoma (HCC) or other malignancies.
  • Previous history of HCC or HCC intervention.
  • Liver cell failure, liver transplantation or renal impairment

结局指标

主要结局

Hepatocellular Carcinoma

时间窗: 24 month

Number of Participants develop New Hepatocellular Carcinoma

次要结局

未报告次要终点

研究者

发起方
Egyptian Liver Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验